SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer.

Related Posts

Colorado could cap payments for Amgen’s Enbrel

Feb 23, 2024

Men taking valproate and their partners warned to use c...

Sep 8, 2024

CD70 CAR-T by UTC Therapeutics for Anaplastic Large Cel...

Aug 10, 2023